FDA grants Fast Track designation to pelareorep in anal cancer

Oncolytics Biotech received Fast Track designation for pelareorep in second-line and later anal cancer, which the company believes validates an estimated $1 billion market. This is the company's third Fast Track designation in gastrointestinal cancers.